ATE385234T1 - Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren - Google Patents

Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren

Info

Publication number
ATE385234T1
ATE385234T1 AT04710346T AT04710346T ATE385234T1 AT E385234 T1 ATE385234 T1 AT E385234T1 AT 04710346 T AT04710346 T AT 04710346T AT 04710346 T AT04710346 T AT 04710346T AT E385234 T1 ATE385234 T1 AT E385234T1
Authority
AT
Austria
Prior art keywords
xanthine derivatives
sulfonamide substituted
substituted xanthine
pepck inhibitors
pepck
Prior art date
Application number
AT04710346T
Other languages
English (en)
Inventor
Louise Foley
Nicholas Huby
Sherrie Pietranico-Cole
Weiya Yun
Pete Dunten
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE385234T1 publication Critical patent/ATE385234T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04710346T 2003-02-19 2004-02-12 Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren ATE385234T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44856203P 2003-02-19 2003-02-19

Publications (1)

Publication Number Publication Date
ATE385234T1 true ATE385234T1 (de) 2008-02-15

Family

ID=32908606

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04710346T ATE385234T1 (de) 2003-02-19 2004-02-12 Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren

Country Status (14)

Country Link
EP (1) EP1599477B1 (de)
JP (1) JP2006515337A (de)
KR (1) KR100728425B1 (de)
CN (1) CN100361992C (de)
AT (1) ATE385234T1 (de)
AU (1) AU2004213124A1 (de)
BR (1) BRPI0407695A (de)
CA (1) CA2514472A1 (de)
DE (1) DE602004011603T2 (de)
ES (1) ES2298722T3 (de)
MX (1) MXPA05008672A (de)
PL (1) PL378555A1 (de)
RU (1) RU2340613C2 (de)
WO (1) WO2004074288A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2310372B1 (de) 2008-07-09 2012-05-23 Sanofi Heterocyclische Verbindungen, Verfahren zu ihrer Herstellung, Arzneimitteln mit diesen Verbindungen und ihre Verwendung
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785450B2 (en) * 2009-06-29 2014-07-22 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP2470552B1 (de) 2009-08-26 2013-11-13 Sanofi Neuartige kristalline heteroaromatische Fluorglycosidhydrate, Pharmazeutika, die diese Verbindungen umfassen, und deren Verwendung
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TWI549947B (zh) * 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
DE60327628D1 (de) * 2002-06-12 2009-06-25 Hoffmann La Roche Amid substituierte xanthin derivate mit gluconeogenesis modulierender wirkung

Also Published As

Publication number Publication date
EP1599477B1 (de) 2008-01-30
EP1599477A1 (de) 2005-11-30
MXPA05008672A (es) 2005-10-18
DE602004011603D1 (de) 2008-03-20
AU2004213124A1 (en) 2004-09-02
KR20050107432A (ko) 2005-11-11
CN100361992C (zh) 2008-01-16
DE602004011603T2 (de) 2009-01-29
JP2006515337A (ja) 2006-05-25
CN1751044A (zh) 2006-03-22
RU2340613C2 (ru) 2008-12-10
WO2004074288A1 (en) 2004-09-02
RU2005128833A (ru) 2006-07-27
CA2514472A1 (en) 2004-09-02
BRPI0407695A (pt) 2006-03-01
KR100728425B1 (ko) 2007-06-13
ES2298722T3 (es) 2008-05-16
PL378555A1 (pl) 2006-05-02

Similar Documents

Publication Publication Date Title
ATE385234T1 (de) Sulfonamidsubstituierte xanthinderivate zur verwendung als pepck-inhibitoren
ATE377004T1 (de) Proteinkinaseinhibitoren
DE60331187D1 (de) Kinaseinhibitoren
CY1111410T1 (el) Αναστολεις τουμπουλινης
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
ATE346070T1 (de) Purinderivate als kinaseinhibitoren
CY1113029T1 (el) Παραγωγα αζαδικυκλο [3.1.0] εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
NI201000059A (es) Inhibidores de la cinasa c-fms.
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
DE69912581D1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
EA200600509A1 (ru) Соединения пиримидотиофена
BR0206738A (pt) Derivados tricìclicos de lactama e de sultama e uso dos mesmos como inibidores de histona desacetilase
BRPI0508464A (pt) sulfonilpirróis
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
BRPI0407841A (pt) inibidores heterocìclicos de quinase
ATE413882T1 (de) 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
ATE517623T1 (de) Verwendung von methylphenidat-derivaten
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
MXPA05009282A (es) Derivados de anilina sustituidos.
ATE364384T1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
NO20090332L (no) 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1599477

Country of ref document: EP

REN Ceased due to non-payment of the annual fee